MegaRobo

MegaRobo ranks as China’s top autonomous agent provider for intelligent laboratory applications by 2024 revenue. The Beijing-based company has built a broad portfolio of robotic automation platforms serving pharmaceutical research, clinical diagnostics, and precision manufacturing sectors across more than 880 client organizations.

Company Overview

Founded in 2016 by Daniel Huang (黄瑜清), Zhixin Qiao (乔志新), and Yan Zhang (张琰), MegaRobo emerged from the founders’ shared vision of applying robotics and AI technologies to transform laboratory workflows. The company name derives from “Mega,” reflecting its mission to handle massive-scale automated operations.

The founding team brought complementary expertise: CEO Huang studied information engineering at Xi’an Jiaotong University and earned an MBA from Tsinghua University; COO Qiao previously served as UMG Project Director at Huawei’s Beijing Research Institute; and Senior VP Zhang specializes in mechanical design and instrumentation.

MegaRobo’s business evolution followed three distinct phases. From 2016 to 2018, the company focused on robotic hardware development, establishing core competencies in control systems and precision mechanics. Between 2018 and 2020, MegaRobo pivoted toward complete solution delivery, recognizing that clients required integrated systems rather than standalone components. Since 2020, the company has concentrated on building fully proprietary intelligent laboratory systems.

Headquarters are located in Beijing’s Changping District, with branch offices in Shenzhen, Shanghai, and Suzhou supporting regional operations.

Core Products

MegaLab Platform

The flagship MegaLab system represents China’s first self-developed universal automated laboratory platform. Centered on robotic manipulators, MegaLab connects diverse laboratory instruments to achieve unattended experimental operations. The platform supports vaccine development, pharmaceutical R&D, and various biotechnology applications.

MegaFluent System

MegaFluent provides a general-purpose laboratory automation software platform that coordinates multiple robotic arms and instruments. The system delivers “sample-in, result-out” fully automated experiments with support for parallel processing and dynamic task scheduling. Applications span life sciences, clinical diagnostics, and chemical research.

Auflo Liquid Handling Workstations

The Auflo series includes multiple configurations for automated pipetting:

• Auflo-T9600: Automated electronic pipette with touchscreen interface
• Auflo-P1200: Four independent 1000μL pipetting channels with adjustable spacing
• Auflo-P800SE: High-precision dual-channel system with 1-20μL or 10-200μL range options

MRQ Drive Controllers

MegaRobo’s proprietary MRQ series multiaxis motor drive controllers feature integrated drive-controller design based on CANOpen Protocol. These components have earned both CNAS and CE certifications, incorporating patented technologies for high precision, low noise operation.

Technology & Innovation

MegaRobo’s technical architecture operates across three integrated layers: perception, conception, and execution. The perception layer captures real-time environmental data; conception handles task planning and decision-making; execution translates plans into precise physical actions.

The company holds over 150 invention patent applications covering robotic automation and AI technologies. Core capabilities include:

• MegaSmooth adaptive speed interpolation smoothing technology
• MegaRobust full digital closed-loop feedback control
• One-piece robot design without external control cabinets

The MegaRobo Kunpeng Laboratory (镁伽鲲鹏实验室), launched in 2019 and upgraded to version 3.0 in 2024, focuses on cell gene editing, high-throughput drug screening, organoid automation, and synthetic biology research.

Market Presence

By 2024 intelligent laboratory revenue, MegaRobo leads Chinese autonomous agent suppliers. The company has served over 880 clients with delivery of hundreds of intelligent automation systems. Notable strategic partners include WuXi AppTec in pharmaceutical services and Bosch in manufacturing automation—both of which also participate as investors.

Revenue grew from RMB 455 million in 2022 to RMB 930 million in 2024, reflecting a 43% compound annual growth rate. Business segments divide between intelligent laboratory (31.7% of 2024 revenue) and intelligent manufacturing (68.3% of 2024 revenue).

Key Milestones

• 2016: Company founded in Beijing by Huang, Qiao, and Zhang
• 2019: MegaRobo Kunpeng Laboratory established
• 2020: Completed Series B financing led by Sinovation Ventures
• 2022: Closed $300M Series C round led by Goldman Sachs, GGV Capital, and Asia Investment Capital
• 2024: Surpassed RMB 900 million in annual revenue
• 2025: Filed for Hong Kong IPO with valuation exceeding RMB 10.5 billion

Frequently Asked Questions

What industries does MegaRobo serve?

MegaRobo provides automation solutions for life sciences (pharmaceutical R&D, clinical diagnostics, biotechnology), precision manufacturing (semiconductors, new energy), and applied chemistry. The company’s largest revenue contribution comes from intelligent manufacturing applications.

Is MegaRobo publicly traded?

MegaRobo remains privately held as of January 2026. The company filed for Hong Kong Stock Exchange listing in mid-2025 following completion of Series D financing that valued the company at over RMB 10.5 billion.

Who are MegaRobo’s major investors?

The company has completed eight funding rounds totaling over RMB 2.7 billion. Key investors include Goldman Sachs Asset Management, Sinovation Ventures (15.07% stake as second-largest shareholder), GGV Capital, WuXi AppTec, Bosch, and CICC.